

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

CAPITAL STRUCTURE

| | |
|-----------------------|--------|
| ASX code | BDA |
| Shares on issue | 69.4m |
| Market Capitalisation | ~\$17m |

BOARD & MANAGEMENT

Mr George Livery
Executive Chairman

Ms Jo Patterson
Chief Executive Officer

Mr Stephen Thompson
Executive Director

Mr Simon O'Loughlin
Non-Executive Director

Mr Simon Taylor
Non-Executive Director

Mr Stephen Kelly
Company Secretary

CONTACT

Level 1, 377 New South Head Rd
Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

Bod to sell and supply its medicinal cannabis for a landmark PTSD trial

- **Bod to sell and supply its medicinal cannabis for landmark Post Traumatic Stress Disorder (PTSD) trial being undertaken by Cannabis Access Clinics**
- **Bod to supply MediCabilis™ product to participants through its pharmacy distribution network generating revenues and growth in patients and prescriptions**
- **Trial measures efficacy of cannabis extract ECs315 in oil form on PTSD sufferers**
- **Trial scheduled to begin immediately**
- **Bod will use the IP generated from the study for future product development, commercialisation and product licencing opportunities following the outcomes of the trial**

Sydney, Australia – 4 June 2019: Cannabis focused healthcare company, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA) is pleased to advise that it will be supplying its pharmaceutical grade cannabis extract, MediCabilis™ 5% CBD ECs315 (MediCabilis™) to sufferers of Post Traumatic Stress Disorder (PTSD), in a landmark 12 month trial facilitated by Cannabis Access Clinics.

PTSD is a particular set of reactions that can develop in people who have experienced a traumatic event, which threatened their life or safety. As a result, sufferers develop feelings of intense fear, helplessness and horror. It is estimated PTSD affects 12% of Australians.

Research partner, Cannabis Access Clinics is facilitating the trial and will manage the process from screening to recruitment process. Specialist research organisation Applied Cannabis Research, will also be assisting in data collection and patient management during the trial.

MediCabilis™ will be prescribed to participants through approved prescribers in the Cannabis Access Clinics network. Participants will then purchase the product, which retails for \$491.00 at any of the pharmacies in Bod’s broad network.

Bod expects to generate revenue from the trial over the 12 month period. The Company will also pursue similar agreements with medical organisations and research partners to replicate this model, further underpinning revenues and medical cannabis product sales for its Pharma business.

Bod will use the intellectual property generated from the trial and following any positive results, will pursue product development, commercialisation and product licencing opportunities with the product used in the study.

Bod Australia CEO Jo Patterson said: “Post Traumatic Stress Disorder is widespread and debilitating on a global scale. The Australian Defence Force has reported that an estimated 90% of members have experienced at least one potentially traumatic event at some time of their life, which may result in symptoms of PTSD.

“We look forward to progressing this trial as it has the potential to significantly strengthen our revenue stream, as well as further validate our product suite.

“Bod is continuing to progress commercialisation and export activities and the Board and management team look forward to updating shareholders on developments in the near term.”

Cannabis Access Clinics Medical Director Dr Nijhawan, commented: “we have first hand experience treating symptoms of PTSD and seeing the positive effects that medicinal cannabis can have on patient outcomes.

“This study will provide valuable insight into how medicinal cannabis is being used and its effect on patient outcomes. It will help build on existing evidence, and support further research and clinical applications. CBD has fewer side effects than the pharmacological therapy currently used, even at high doses.”

Dr John Barlow, principal researcher at Applied Cannabis Research commented: “Through the TGA, Australia has a stringent medical compliance framework for medicinal cannabis that requires precise dosing and monitoring of patients, making it an ideal location for this type of research. We hope to add to the increasing body of knowledge about medicinal cannabis and the potential for benefit to patients suffering from the effects of traumatic experiences.”

– ENDS –

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is rapidly building an integrated cannabis business, underpinned by agreements with international counterparties Linnea SA, a leading Swiss botanicals extracts manufacturer and iX Biopharma Limited, a late stage Singapore-listed pharmaceutical company. Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia’s largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

BODAUSTRALIA.COM

About Applied Cannabis Research:

Applied Cannabis Research is a specialist contract research organisation providing medicinal cannabis companies with services to assess the outcome of using their products to treat patients. Applied Cannabis Research conducts a range of studies including observational and clinical trials.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538